CME Group (CME) is back in focus after regulators approved an expanded cross margining arrangement with the Depository Trust & Clearing Corporation, potentially improving capital efficiency for clients trading U.S. Treasury and interest rate derivatives.

After a run of product launches across interest rate, equity dividend and cryptocurrency derivatives, CME Group’s recent 7 day and 30 day share price returns of 4.37% and 6.47% respectively contrast with a 1 year total shareholder return of 14.64%, with longer term total shareholder returns of 74.75% over 3 years and 73.07% over 5 years. This performance suggests momentum has been broadly positive over time.

If you are watching how new derivatives and clearing efficiencies are reshaping opportunities, it may be worth casting the net wider with the 22 cryptocurrency and blockchain stocks

With CME trading around $287.45, some readers may see a global derivatives leader with a long record of total returns and fresh growth initiatives. The key question is whether that price still represents a sensible entry point or whether the market is already pricing in what comes next.

Most Popular Narrative: 8% Undervalued

At a last close of $287.45 versus a narrative fair value of $311.67, analysts see some upside baked into their detailed long term modeling.

New product innovations (e.g., Micro contracts, expansion into crypto, FX Spot+), ongoing tech-driven operating efficiencies (cloud migration and tokenization initiatives), and strengthening of strategic partnerships (such as the long-term NASDAQ index license extension and Google Cloud collaboration) are enhancing operating leverage and EBITDA/net margin performance.

Curious what kind of revenue growth, margin shifts, and future earnings multiple underpin that fair value gap? The narrative leans on specific volume, profitability, and valuation assumptions that are far from conservative yet not outlandish either.

Result: Fair Value of $311.67 (UNDERVALUED)

However, this narrative could be disrupted if DeFi alternatives gain traction or if regulators tighten derivatives rules, both of which could pressure CME’s volumes and fees.

Another Angle on Value

While analysts see a fair value of $311.67 and describe CME as 8% undervalued, the SWS DCF model tells a different story. On that approach, CME at $287.45 sits above an estimated future cash flow value of $244.08, which points to an overvalued result instead.

This kind of gap between earnings based and cash flow based models raises an obvious question for you as an investor: which set of assumptions about CME's future cash generation feels more realistic?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CME Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 63 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on valuation and sentiment running both cautious and optimistic, it makes sense to look at the underlying data yourself and move quickly to shape your own view, starting with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If you stop at one stock, you risk missing opportunities elsewhere, so use these focused stock lists to pressure test your thinking and spot fresh ideas.

• Upgrade your watchlist with companies that pair quality and attractive pricing by scanning the 63 high quality undervalued stocks.
• Strengthen your income stream by reviewing the 13 dividend fortresses and see which high yield names might deserve a closer look.
• Reduce portfolio stress by hunting for financially resilient names using the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.